- People also ask
Positive Phase III Results for Genentech’s Gazyva Show Superiority …
WEB5 days ago · Gazyva® (obinutuzumab) is a prescription medicine used: With the chemotherapy drug, chlorambucil, to treat chronic lymphocytic leukemia (CLL) in adults …
Positive phase III results for Roche’s Gazyva/Gazyvaro show
WEB5 days ago · Gazyva®/Gazyvaro® (obinutuzumab) is a Type II engineered humanised monoclonal antibody designed to attach to CD20, a protein found on certain types of B …
Gazyva® Shows Positive Results in Phase 3 Lupus Nephritis Trial
WEBSeptember 25, 2024. The Lupus Research Alliance (LRA) and clinical research affiliate Lupus Therapeutics (LT) are excited to share positive news of the Phase 3 REGENCY …
UPDATE: Positive Phase III Clinical Trial Results Announced for …
WEB5 days ago · Genentech announced positive results from the Phase III study (REGENCY) of Gazyva (Obinutuzumab) for people with active lupus nephritis (LN). Gazyva is an …
Significant benefit seen with obinutuzumab in lupus nephritis trial
WEB12 hours ago · Positive topline results were announced from a phase 3 study of obinutuzumab in patients with lupus nephritis. Obinutuzumab, a monoclonal antibody …
Genentech: Press Releases | Wednesday, Sep 25, 2024
WEBSep 25, 2024 · About Gazyva in Kidney Diseases. Gazyva ® (obinutuzumab) is a Type II engineered humanized monoclonal antibody designed to attach to CD20, a protein found on certain types of B cells. …
Positive Phase III results for Roche’s Gazyva/Gazyvaro …
WEB1 day ago · Swiss pharma giant Roche has announced positive top-line results from the Phase III REGENCY study of Gazyva/Gazyvaro (obinutuzumab) in people with active lupus nephritis. ... Unfettered …
Positive phase III results for Roche’s Gazyva/Gazyvaro show …
WEB5 days ago · Basel, 26 September 2024 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today positive topline results from the phase III REGENCY study of …
Roche looks to grow Gazyva's reach with phase 3 lupus nephritis win
WEB5 days ago · After collecting a handful of oncology approvals since its first leukemia nod in 2013, Roche’s Biogen-partnered Rituxan successor, Gazyva, is chasing new horizons in …
Roche's Lupus Study for Gazyva Meets Primary & Key Secondary …
WEB6 days ago · Roche RHHBY announced positive top-line data from a late-stage study of its marketed drug, Gazyva/Gazyvaro (obinutuzumab), to treat patients with active lupus …
